Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels: Implications for venous bypass graft failure

Circulation

Volumn 95, Issue 7, 1997, Pages 1870-1876

  Yang, Zhihong ^c   Ruschitzka, Frank ^c   Rabelink, Ton J ^c   Noll, Georg ^c   Julmy, Friedgard ^c   Joch, Hana ^c   Gafner, Verena ^c   Aleksic, Ivan ^a   Althaus, Ulrich ^c   Lüscher, Thomas F ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NONE

Author keywords

arteries; grafting; receptors; veins

Indexed keywords

DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; LEPIRUDIN; MITOGEN ACTIVATED PROTEIN KINASE; THROMBIN; THROMBIN INHIBITOR; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DNA SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; INTERNAL MAMMARY ARTERY; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

EID: 0030934016     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.7.1870     Document Type: Article

References (36)

1. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LAR, Gill CC, Taylor PC, Sheldon WC, Proudfit WL. Influence of the internal mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986; 314:1-6.
2. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, Von Segesser L, Yang Z, Turina M, Grädel G, Weber E, Bühler FR. Difference between endothelium-dependent relaxations in arterial and in venous coronary bypass grafts. N Engl J Med. 1988; 319:462-467.
3. Yang Z, Stulz P, Von Segesser L, Bauer E, Turina M, Lüscher TF. Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet. 1991;337:939-943.
4. Yang Z, Diederich D, Schneider K, Siebenmann R, Stulz P, Von Segesser L, Turina M, Bühler FR, Lüscher TF. Endothelium-derived relaxing factor and protection against contractions induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein. Circulation. 1989;80:1041-1048.
5. Predel H-G, Yang Z, Von Segesser L, Turina M, Bühler FR, Lüscher TF. Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet. 1992; 340:878-879.
6. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90:1522-1536.
7. Israel DH, Adams PC, Chesebro JH, Fuster V. Antithrombotic therapy in the coronary vein graft patient. Clin Cardiol. 1991;14: 283-295.
8. Berndt MC, Phillips DR. Platelet membrane proteins: composition and receptor function. In: Gordon JL, ed. Platelets in Biology and Pathology. Amsterdam, Netherlands: Elsevier/North Holland; 1981: 43-74.
9. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW II. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science. 1983;220:728-731.
10. De Mey JG, Vanhoutte PM. Endothelium-dependent inhibitory effects of acetylcholine, adenosine, thrombin, and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther. 1982;222: 166-173.
11. Tesfamariam B. Distinct receptors and signaling pathways in α-thrombin- and thrombin receptor peptide-induced vascular contractions. Circ Res. 1994;74:930-936.
12. 2. Circulation. 1994; 89:2266-2272.
13. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:199-205.
14. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-1068.
15. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
16. Huang CL, Ives HE. Growth inhibition by protein kinase C late in mitogenesis. Nature. 1987;329:849-850.
17. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17(suppl B):77B-88B.
18. Wilcox JN. Thrombin and other potential mechanisms underlying restenosis. Circulation. 1991;84:432-435.
19. Vu TKH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
20. Hung DT, Vu TKH, Nelken NA, Coughlin SR. Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol. 1992;116:827-832.
21. 2 independent of the mitogen-activated protein kinases ERK1/2. J Biol Chem. 1995; 270:14816-14823.
22. Shankar R, De la Motte CA, Poptic EJ, DiCorleto PE. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem. 1994;269:13936-13941.
23. Berk BC, Taubman MB, Griendling KK, Cragoe EJ, Fenton JW, Brock TA. Thrombin-stimulated events in cultured vascular smooth muscle cells. Biochem J. 1991;274:799-805.
24. van Obberghen-Schilling E, Pouysségur J. α-Thrombin receptors and growth signaling. Semin Thromb Hemost. 1993;19:378-385.
25. Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem. 1993;268:17896-17901.
26. MAPK (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol. 1992;6:845-854.
27. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A. 1993;90:5889-5892.
28. MAPK are required for fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90:8319-8323.
29. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden L, Salam TA, Kelly AB, Harker LA, Runge M. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994;75: 1029-1038.
30. Kern WH, Dermer GB, Lindesmith GG. The intimai proliferation in aortocoronary saphenous vein grafts: light and electron microscopic studies. Am Heart J. 1972;84:771-777.
31. Smith SH, Geer JC. Morphology of saphenous vein coronary bypass grafts: 7 to 116 months after surgery. Arch Pathol Lab Med. 1983; 107:13-18.
32. Yang Z, Von Segesser L, Bauer E, Stulz P, Turina M, Lüscher TF. Different activation of endothelial L-arginine and cyclooxygenase pathway in human internal mammary artery and saphenous vein. Circ Res. 1991;68:52-60.
33. Jaffe E, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52: 2745-2756.
34. Yang Z, Noll G, Lüscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 1993;88:832-836.
35. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996;381:516-519.
36. Singh RN. Atherosclerosis and internal mammary arteries. Cardiovasc Intervent Radiol. 1983;6:72-77.